| 183.87 3.48 (1.93%) | 07-21 13:09 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 226.38 | 1-year : | 264.42 |
| Resists | First : | 193.82 | Second : | 226.38 |
| Pivot price | 186.29 |
|||
| Supports | First : | 168.52  |
Second : | 152.88 |
| MAs | MA(5) : | 182.66 |
MA(20) : | 184.33 |
| MA(100) : | 140.1 |
MA(250) : | 95.82 |
|
| MACD | MACD : | 5.5 |
Signal : | 7.4 |
| %K %D | K(14,3) : | 41.8 |
D(3) : | 47 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 193.82 | Low : | 34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RVMD ] has closed above bottom band by 27.5%. Bollinger Bands are 50.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 190.09 - 191.01 | 191.01 - 191.93 |
| Low: | 177.6 - 178.73 | 178.73 - 179.84 |
| Close: | 178.31 - 180.09 | 180.09 - 181.85 |
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Mon, 20 Jul 2026
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Mon, 13 Jul 2026
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Titan with a Promising 7.17% Upside - DirectorsTalk Interviews
Fri, 03 Jul 2026
Why Revolution Medicines (RVMD) Is Up 6.2% After Early Zoldonrasib Pancreatic Cancer Data And What's Next - Yahoo Finance
Thu, 02 Jul 2026
Revolution Medicines Presents Phase 1/2 Clinical Data for - GlobeNewswire
Wed, 24 Jun 2026
Revolution Medicines puts pancreatic cancer combo data on ESMO stage - Stock Titan
Mon, 22 Jun 2026
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 213 (M) |
| Shares Float | 194 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 95.9 (%) |
| Shares Short | 12,880 (K) |
| Shares Short P.Month | 11,590 (K) |
| EPS | -7.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.6 % |
| Return on Equity (ttm) | -76.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -5.32 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1,060 (M) |
| Levered Free Cash Flow | -606 (M) |
| PE Ratio | -25.8 |
| PEG Ratio | 0 |
| Price to Book value | 24.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -36.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|